The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.
Talia Golan
No relevant relationships to disclose
Ayala Hubert
No relevant relationships to disclose
Amotz Shemi
Employment or Leadership Position - Silenseed
Stock Ownership - Silenseed
Amiel Segal
No relevant relationships to disclose
Alan Dancour
No relevant relationships to disclose
Elina Zorde Khvalevsky
Employment or Leadership Position - Silenseed
Research Funding - Silenseed
Eliel Ben-David
No relevant relationships to disclose
Stephen Raskin
No relevant relationships to disclose
Yuri Goldes
No relevant relationships to disclose
Yael Inbar
No relevant relationships to disclose
Maor Lahav
No relevant relationships to disclose
Avi Domb
No relevant relationships to disclose
Eithan Galun
Consultant or Advisory Role - Silenseed
Stock Ownership - Silenseed